Delivery Order SPE2DB25D3306-SPE2DB25FUCXZ
- Not listed
- The Defense Logistics Agency awarded a $7,509.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen injections on August 19, 2025, with ultimate completion scheduled for August 20, 2025. This competitive award, placed under no set-aside designation, represents a child delivery order issued against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical prime vendor agreement...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections (0.5 mL units) with a ceiling value of $1,659.37. This firm fixed-price delivery order, which is set to be completed by August 15, 2025, will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a non-competitive delivery order issued under AmerisourceBergen's existing indefinite delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections, with a contract ceiling value of $15,472.34. This is a firm fixed-price delivery order with an ultimate completion date of July 29, 2025, and represents a non-competitive set-aside award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $16,403.16 delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injectors. This firm fixed price, non-competitive delivery order is set to be completed by August 29, 2025, with performance executed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $15,251.60 on August 15, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections. The contract, designated as a firm fixed price delivery order with an ultimate completion date of August 18, 2025, represents a non-competitive set-aside award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under the...
- The Defense Logistics Agency awarded a $24,402.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injectors on August 21, 2025, with completion scheduled for August 22, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion comprehensive pharmaceutical supply vehicle running through December 2026. The award was made...
- The Defense Logistics Agency awarded a delivery order valued at $2,287.74 to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections. This is a firm fixed-price delivery order with no set-aside designation, demonstrating competitive award status. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 6, 2025. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Zepbound 2.5 mg/0.5 ml pen injections with a ceiling value of $43,927.89. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is expected to be completed by July 22, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a $28,634.71 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pen injectors on August 11, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999, which runs through December 2026. The performance location is the company's corporate office in Conshohocken, Pennsylvania, with...
- The Defense Logistics Agency awarded a delivery order valued at $7,403.76 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injectors. This is a firm fixed-price, non-set-aside contract with a completion date of August 14, 2025, and performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX,...
- SPE2DB25D3306Indefinite Delivery Contract
- SPE2DB25D3306-SPE2DB25FUCXZDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injections with a ceiling value of $5,141.16. This is a firm fixed-price delivery order with no set-aside designation, issued under a competitive procurement process. The order is set for completion by September 11, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania facility. This delivery order is a child contract issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. AmerisourceBergen Drug Corp, one of the nation's largest pharmaceutical distributors, serves as a critical supplier to the Defense Logistics Agency's Medical Supply Chain, providing a comprehensive portfolio of pharmaceuticals and medical supplies to support military healthcare systems. As a major pharmaceutical distributor headquartered in Pennsylvania, the company maintains an extensive federal contract portfolio delivering medications across multiple therapeutic domains to military and veteran healthcare systems. This particular order for Zepbound, a GLP-1 receptor agonist used in diabetes and weight management treatment, reflects the company's role in supplying specialty pharmaceuticals to the Department of Defense's healthcare infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.1k | 9/10/25 |